DERMATOLOGY

Order Set

dyVee.	
hėa	lth.
INFUSIO	

PHONE 515.225.2930 | FAX 515.559.2495

Phone:

Patient Information Fax completed form, insurance information and clinical documentation to 515.5

New to Therapy

lbs. (required) Allergies:

Patient Name:		
Patient Status:	New to Therapy	Continuing

DOB: **Next Treatment Date:**

Medical Information

Patient Weight:

Therapy Order			
Diagnosis	Infusion Orders	Refills	
Cellulitis MRSA Skin infection/Abscess ICD-10:	Cubicin 4 mg/kg IV 6 mg/kg IV Dalvance Daily for		
Dermatomyositis Dermatopolymyositis Phemphigoid/Pemphigus Other: ICD-10: CIU ICD-10:	IVIg orders:mg/kg ORgm/kg IV xday(s) OR divided overday(s) Frequency: Everyweeks x1 year OR1 time dose only Preferred brand:(Hy-Vee Health to choose if not indicated) Additional Ig orders:		
Pemphigus vulgaris	Note: Patient must have an EpiPen in their possession on their appointment date. Rituximab or rituximab biosimilar as required by patient's insurance Do not substitute. Infuse the following rituximab product:		
Psoriatic arthritis Psoriasis Plaque psoriasis ICD-10:	Infliximab or infliximab biosimilar as required by patient's insurance Do not substitute. Infuse the following infliximab product: For Hy-Vee Health use only. Brand: Dose: mg/kg Prequency: Every weeks OR weeks 0, 2, and 6, then every 8 weeks Simponi aria Initial dose: 2 mg/kg IV at weeks 0 and 4, then every 8 weeks Maintenance dose: 2 mg/kg IV every 8 weeks Stelara 45 mg Sub-Q initially and 4 weeks later, followed by 45 mg every 12 weeks (≤ 100kg) 90 mg Sub-Q initially and 4 weeks later, followed by 90 mg every 12 weeks (>100kg) Maintenance dose: 45 mg Sub-Q every 12 weeks OR 90 mg Sub-Q initially and 4 weeks 0 and 4, then every 12 weeks (>100kg) Maintenance dose: 45 mg Sub-Q every 12 weeks OR 90 mg Sub-Q initially and 4 weeks 0 and 4, then every 12 weeks (>100kg) Maintenance dose: 45 mg Sub-Q every 12 weeks OR 90 mg Sub-Q every 12 weeks 90 mg Sub-Q every 12 weeks Ilumya Initial dose: 100 mg Sub-Q every 12 weeks Cimzia 200 mg Sub-Q every 2 weeks 400 mg Sub-Q every 2 weeks 400 mg Sub-Q at weeks 0, 2 and 4, followed by 200 mg 400 mg every 2 weeks		
Diph Additional premedications: Lab orders:	1000 mg 500 mg PO, please choose 1 antihistamine: nenhydramine 25 mg PO Loratadine 10 mg PO Cetirizine 10 mg PO Quzyttir 10 mg IVP Solu-Medrol mg IVP Solu-Cortef mg IVP Other:		
Physician Information			
•	ng our services, you are authorizing Hy-Vee Health and its employees to serve as your prior authorization and specialty	pharmacy	

Continuing Therapy

designated agent in dealing with medical and prescription insurance companies.

Provider Name:	ovider Name: Signature:						Date:	
Provider NPI:	Ph	one:	Fax		Cor	ntact Person:		
Opt out of Hy-Vee	e Health selecting site of car	e (if checked, ple	ase list site of care):					
Service Areas								
Des Moines, IA	West Des Moines, IA	Chicago, IL	Omaha, NE	Buffalo, NY	Dallas, TX	Phoenix, AZ	Other	

HY-VEEHEALTHINFUSION.COM

IMPORTANT NOTICE: This fax is intended to be delivered only to the named addressee and contains material that is confidential, privileged property or exempt from disclosure under applicable law. If you are not the named addressee, you should not disseminate, distribute or copy this fax. Please notify the sender immediately and destroy all copies if you have received this document in error.

Hyvee health

COMPREHENSIVE SUPPORT FOR DERMATOLOGY THERAPY

Patient Information

Patient Name: DO	DB:			
Required Documentation for Referral Processing & Insurance Approv	ral			
Include <u>signed</u> and <u>completed</u> order (MD/prescriber to complete page 1)				
Include patient demographic information and insurance information				
Include patient's medication list				
Supporting clinical notes to include any past tried and/or failed therapies, intolerance, benefits or contraindications to conventional therapy				
For biologic orders, has the patient had a documented contraindication/intolerance or	failed trial of a conventional therapy (i.e., steroids)?			
Yes No				
If yes, which drug(s)?				
For biologic orders, does the patient have a contraindication/intolerance or failed trial to any other biologic (i.e., Stelara, Cimzia)?				
Yes No				
If yes, which drug(s)?				
Include labs and/or test results to support diagnosis				
If applicable – Last known biological therapy: and last date received:	. If patient is switching to biologic			
therapies, please perform a washout period of weeks prior to starting ordered biologic therapy.				
Other Medical Necessity:				
Required prescreening (based on drug therapy)				
TB screening test completed within 12 months – attach results				
Required for: Cimzia, Infliximab, Stelara, Ilumya, Simponi aria				
Positive Negative				

Hepatitis B screening test completed. This includes Hepatitis B antigen and Hepatitis B core antibody total (not IgM)

Required for: Cimzia, Infliximab, Rituximab, Simponi

Positive Negative

Baseline creatinine Required for IVIG

*If TB or Hepatitis B results are positive, please provide documentation of treatment or medical clearance, and a negative CXR (TB+).

Hy-Vee Health will complete insurance verification and submit all required documentation for approval to the patient's insurance company for eligibility. Our team will notify you if any additional information is required. We will review financial responsibility with the patient and refer him/her to any available co-pay assistance as needed. Thank you for the referral.

HY-VEEHEALTHINFUSION.COM

IMPORTANT NOTICE: This fax is intended to be delivered only to the named addressee and contains material that is confidential, privileged property or exempt from disclosure under applicable law. If you are not the named addressee, you should not disseminate, distribute or copy this fax. Please notify the sender immediately and destroy all copies if you have received this document in error.